Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Tremelimumab in advanced and relapsed germ cell tumors
2016-001688-35Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in germ cell tumor (GCT) comparing Durvalumab monotherapy with Durvalumab + Tremelimumab (2 arms). Primary endpoint: Objective response rate (CR + PR with negative tumor markers). Started Jun 2021; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2016-001688-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001688-35.